Download presentation
Presentation is loading. Please wait.
Published byJean-Luc René Modified over 5 years ago
1
MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187). Results (p = 0.92) Death or hospitalization: 62.7% subjects in the escitalopram group vs. 63.6% subjects in the placebo group (p = 0.92) Lower-risk patients appeared to derive more benefit from escitalopram vs. placebo (p for interaction = 0.002) 62.7 63.6 % Conclusions Among patients with chronic systolic heart failure and comorbid depression, escitalopram did not reduce death/hospitalization, or improve depression symptoms There was possible benefit among younger patients with less comorbidity Escitalopram Placebo Presented by Dr. Christiane Angermann at ACC 2015
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.